We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov Menu

CP-547,632 in Treating Patients With Recurrent or Persistent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

This study has been completed.
ClinicalTrials.gov Identifier:
First Posted: November 9, 2004
Last Update Posted: December 19, 2013
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
National Cancer Institute (NCI)
Information provided by:
National Cancer Institute (NCI)

RATIONALE: CP-547,632 may stop the growth of tumor cells by blocking the enzymes necessary for their growth and by stopping blood flow to the tumor.

PURPOSE: This phase II trial is studying how well CP-547,632 works in treating patients with recurrent or persistent ovarian cancer, primary peritoneal cancer, or fallopian tube cancer.

Condition Intervention Phase
Fallopian Tube Cancer Ovarian Cancer Primary Peritoneal Cavity Cancer Drug: CP-547,632 Phase 2

Study Type: Interventional
Study Design: Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase II Open-Label, Multi-Center Study of CP-547, 632, an Oral Tyrosine Kinase Inhibitor of VEGFR-2, in Subjects With Recurrent or Persistent Small-Volume Epithelial Ovarian Cancer, Primary Peritoneal Serous Cancer, or Fallopian Tube Cancer

Resource links provided by NLM:

Further study details as provided by National Cancer Institute (NCI):

Study Start Date: December 2004
Study Completion Date: February 2005
Detailed Description:



  • Determine the efficacy of CP-547,632, in terms of clinical response benefit (CA 125 response [complete response (CR) or partial response (PR)] or stable disease ≥ 16 weeks), in patients with recurrent or persistent small-volume ovarian epithelial, primary peritoneal serous, or fallopian tube cancer.


  • Determine progression-free survival of patients treated with this drug.
  • Determine CA 125 response (CR or PR) rate in patients treated with this drug.
  • Determine duration of CA 125 response in patients treated with this drug.
  • Determine the safety of this drug in these patients.
  • Correlate the steady state plasma concentration of this drug with efficacy and toxicity in these patients.
  • Correlate clinical outcome with an angiogenic profile derived from measurement of serum vascular endothelial growth factor, basic fibroblast growth factor, and interleukin-8 in patients treated with this drug.
  • Determine changes in the Hospital Anxiety and Depression Scale (HADS) in patients treated with this drug.

OUTLINE: This is an open-label, multicenter study.

Patients receive oral CP-547,632 once daily on days 1-28. Treatment repeats every 28 days for up to 13 courses in the absence of disease progression or unacceptable toxicity.

Patients are followed at 30 days and then every 3 months for 2 years.

PROJECTED ACCRUAL: A total of 10-29 patients will be accrued for this study within 1 year.


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No


  • Histologically confirmed ovarian epithelial, primary peritoneal serous, or fallopian tube cancer

    • Recurrent or persistent disease

      • Elevated CA 125, defined as ≥ 40 U/mL on 2 separate consecutive measurements taken ≥ 1 week apart
  • No definitive disease OR small-volume disease (≤ 2 cm by spiral or conventional CT scan or clinical exam)
  • Asymptomatic disease



  • 26 and over (age 18 to 25 allowed provided there is closure of the epiphyses on radiography)

Performance status

  • ECOG 0-1

Life expectancy

  • More than 6 months


  • Absolute neutrophil count ≥ 1,500/mm^3
  • Platelet count ≥ 100,000/mm^3
  • No bleeding disorders
  • No hemorrhage ≥ grade 2 within the past 12 months


  • Bilirubin ≤ 1.5 times upper limit of normal (ULN)
  • Alkaline phosphatase ≤ 2.5 times ULN
  • ALT and/or AST ≤ 2.5 times ULN
  • Albumin ≥ 3.2 g/dL
  • PT/PTT ≤ 1.5 times ULN
  • INR ≤ 1.5


  • Creatinine ≤ 1.5 times ULN OR
  • Creatinine clearance ≥ 60 mL/min


  • QTc ≤ 460 msec by ECG
  • No unstable angina within the past 6 months
  • No decompensated congestive heart failure within the past 6 months
  • No myocardial infarction within the past 6 months
  • No serious cardiac arrhythmias or conduction abnormalities, including any history of recurrent ventricular arrhythmia, within the past 6 months
  • No cardiomyopathy
  • No history of syncope associated with arrhythmia
  • No uncontrolled hypertension within the past 3 weeks, defined as systolic blood pressure > 150 mm Hg or diastolic blood pressure > 90 mm Hg on ≥ 2 of 3 blood pressure readings taken ≥ 5 minutes apart
  • No thrombotic cardiovascular events, including transient ischemic attacks, within the past 12 months


  • Able to take oral medication
  • No malabsorption syndromes
  • No active gastrointestinal bleeding (hematemesis, hematochezia, or melena), unrelated to cancer, within the past 3 months
  • No requirement for IV alimentation


  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception during and for 3 months after study participation
  • No active infection
  • No uncontrolled diabetes
  • No dementia, altered mental status, or uncontrolled psychiatric illness that would preclude giving informed consent or study compliance
  • No other serious uncontrolled medical disorder that would preclude study participation
  • No other active malignancy within the past 3 years except treated limited stage basal cell or squamous cell skin cancer or carcinoma in situ of the breast or cervix


Biologic therapy

  • No prior exposure to mouse antibodies
  • No prior vascular endothelial growth factor (VEGF) or VEGF-receptor targeted therapy
  • No other prior antiangiogenic anticancer therapy, including thalidomide
  • No concurrent prophylactic colony-stimulating factors (i.e., filgrastim [G-CSF] or sargramostim [GM-CSF])
  • No concurrent immunotherapy


  • Prior chemotherapy allowed provided patient received only a first-line platinum-based chemotherapy regimen with or without systemic consolidation chemotherapy
  • At least 3 weeks since prior chemotherapy and recovered (excluding alopecia)
  • No concurrent chemotherapy

Endocrine therapy

  • At least 3 weeks since prior hormonal therapy for ovarian cancer and recovered
  • Concurrent hormone replacement therapy allowed
  • No concurrent chronic oral or IV corticosteroids
  • No concurrent hormonal therapy, including tamoxifen


  • No concurrent radiotherapy


  • More than 4 weeks since prior major surgical procedure
  • No prior gastric resection


  • More than 3 weeks since prior investigational therapy
  • More than 4 weeks since prior major medical interference with the peritoneum or pleura
  • More than 3 months since prior treatment for active ulcer disease
  • No prior consolidation intraperitoneal therapy using cytotoxic agents for ovarian cancer
  • No concurrent antiarrhythmics

    • Beta blockers or calcium channel blockers used for other indications allowed
  • No concurrent grapefruit juice
  • No concurrent therapeutic anticoagulant therapy or chronic daily aspirin > 325 mg/day

    • Concurrent low-dose anticoagulants for maintenance of central venous access allowed
  • No other concurrent experimental or anticancer therapy for the primary disease
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00096239

United States, California
Jonsson Comprehensive Cancer Center, UCLA
Los Angeles, California, United States, 90095-1781
Sponsors and Collaborators
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)
Principal Investigator: Mark D. Pegram, MD Jonsson Comprehensive Cancer Center
  More Information

ClinicalTrials.gov Identifier: NCT00096239     History of Changes
Other Study ID Numbers: CDR0000390237
First Submitted: November 9, 2004
First Posted: November 9, 2004
Last Update Posted: December 19, 2013
Last Verified: February 2005

Keywords provided by National Cancer Institute (NCI):
recurrent ovarian epithelial cancer
primary peritoneal cavity cancer
fallopian tube cancer

Additional relevant MeSH terms:
Ovarian Neoplasms
Fallopian Tube Neoplasms
Peritoneal Neoplasms
Endocrine Gland Neoplasms
Neoplasms by Site
Ovarian Diseases
Adnexal Diseases
Genital Diseases, Female
Genital Neoplasms, Female
Urogenital Neoplasms
Endocrine System Diseases
Gonadal Disorders
Fallopian Tube Diseases
Abdominal Neoplasms
Digestive System Neoplasms
Digestive System Diseases
Peritoneal Diseases